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OBJECTIVE: To determine the serum levels of interferon alpha in childhood-onset systemic lupus erythematosus
patients, their first-degree relatives and healthy controls and to evaluate the associations between serum interferon
alpha and disease activity, laboratory findings and treatment features.
METHODS: We screened consecutive childhood-onset systemic lupus erythematosus patients in a longitudinal
cohort at the pediatric rheumatology unit of the State University of Campinas between 2009 and 2010. All patients
demonstrated disease onset before the age of 16. Disease status was assessed according to the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index (SDI). Interferon alpha levels were measured using an enzyme-linked
immunoabsorbent assay.
RESULTS: We included 57 childhood-onset systemic lupus erythematosus patients (mean age 17.33¡4.50), 64 first-
degree relatives (mean age 39.95¡5.66), and 57 healthy (mean age 19.30¡4.97) controls. Serum interferon alpha
levels were significantly increased in childhood-onset systemic lupus erythematosus patients compared to their first-
degree relatives and healthy controls. Interferon alpha levels were significantly increased in patients with positive
dsDNA antibodies, patients with cutaneous vasculitis, patients with new malar rash and patients who were not
receiving medication. Interferon alpha levels correlated with C3 levels and systemic lupus erythematosus Disease
Activity Index scores. In addition, we observed an inverse correlation between patient age and interferon alpha levels.
CONCLUSION: Interferon alpha may play a role in the pathogenesis of childhood-onset systemic lupus
erythematosus, especially in cutaneous manifestations and dsDNA antibody formation. The observation that
interferon alpha levels are increased in patients who are not taking medication should be investigated in
longitudinal studies to determine whether elevated interferon alpha levels may predict systemic lupus
erythematosus flares.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a prototypical
autoimmune disease characterized by diverse clinical
manifestations ranging from malar rash to renal involve-
ment (1,2). Immune system disorders and abnormalities in
cytokine production have been described in patients with
SLE (1). The pathogenesis of SLE is multifactorial and is
likely driven by a complex combination of genetic and
environmental factors, which leads to an irreversible failure
of immunologic self-tolerance (3).
Approximately 20% of all SLE patients experience disease
onset prior to the age of 16 (4). Childhood-onset SLE
demonstrates a different phenotype than adult-onset SLE.
Renal (50%-67%), neurological (22-95%) and hematological
(77%) involvement in addition to fever and lymphadeno-
pathy areobserved more frequently in pediatric patientsthan
in patients with adult-onset SLE (4,5-11). In addition, child-
hood-onset SLE is associated with significantly more active
diseases, both at disease onset and over time, compared to
adult-onset SLE (9). The outcome of childhood-onset disease
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157is also generally worse than that of adult-onset disease (4,12).
The awareness that SLE in childhood is a potentially fatal
disease, that atypical presentations are very common, and
that aggressive treatment should be introduced early in the
course of the disease have significantly improved survival in
patients with childhood-onset SLE (13,14).
There is strong evidence indicating that cytokines play a
role in the pathogenesis of SLE (15,16). The first cytokine
abnormality documented in SLE was an increased serum
level of interferon (IFN), subsequently characterized as IFN-
a, which is produced mainly by leukocytes (17). Elevated
serum IFN-a has also been observed in adult-onset SLE, and
IFN-a levels correlate with both disease activity and disease
severity (15,17,18). Associations have also been observed
between IFN-a levels and several markers of immune
activation, such as complement activation and double-
stranded DNA (dsDNA) antibody titers (15). However, the
role of IFN-a in childhood-onset SLE has not been
investigated.
The aim of our study was to determine the serum levels of
IFN-a in childhood-onset SLE patients, their first-degree
relatives and healthy controls. In addition, we evaluated the
association of IFN-a with disease activity, laboratory
findings and treatment features.
METHODS
Subjects
Fifty-seven consecutive childhood-onset SLE patients
followed at the Pediatric Rheumatology Outpatient Clinic
of the State University of Campinas were invited to
participate in this cross-sectional study. Patients were
included in the present study if they (i) fulfilled at least
four of the American College of Rheumatology (ACR)
criteria (19), (ii) were younger than 16 years of age at disease
onset, and (iii) had a follow-up duration of at least 6 months.
Sixty-four first-degree relatives and 57 healthy controls
without a history of any chronic disease (including auto-
immune diseases) were included as control groups. The
healthy controls were matched for age, sex and demo-
graphic background. This study was approved by the
ethics committee at our institution, and informed written
consent was obtained from each participant and/or legal
guardian.
Clinical features
The medical histories and clinical and serological char-
acteristics of each patient were entered into a computer
database at the time of SLE diagnosis. The following
variables were included in this database: onset of disease,
defined as the age at which the first symptoms clearly
attributable to SLE occurred; age at diagnosis, defined as the
age at which the patients fulfilled four or more of the 1982
revised criteria for the classification of SLE (19); and follow-
up time, defined as the time from disease onset until May
2010.
All clinical manifestations and laboratory findings were
recorded at disease onset on a quarterly basis throughout
the follow-up period and on the day of blood withdrawal.
Nephritis was defined as proteinuria exceeding 0.5 g/L
with abnormal urinary sediment and/or histological find-
ings. Nephrotic syndrome was defined as proteinuria in
excess of 3 g/day. Hematological abnormalities were
ascribed to lupus only in the absence of bone-marrow
suppression (leukopenia ,4000 cells/mm
3, thrombocytope-
nia ,100,000 cells/mm
3, and hemolytic anemia). We also
assessed the presence of malar rash, discoid lesions,
subacute cutaneous lesions, cutaneous vasculitis, photosen-
sitivity, oral ulcers, arthritis, and serositis. Neurological and
psychiatric involvement was defined according to the ACR
guidelines (20).
The treatment prescribed at the time of blood withdrawal
and any adverse events related to medication use were
recorded. Doses of oral and parenteral corticosteroids were
analyzed and converted to the equivalent doses of pre-
dnisone.
Laboratory studies
Antinuclear antibody (ANA) levels were determined by
indirect immunofluorescence using mouse liver as a sub-
strate and were regarded as positive if the titers were higher
than 1540. The levels of dsDNA antibodies were determined
by indirect immunofluorescenceusing Crithidia as a substrate
and were considered positive if they were higher than 1510.
The levels of precipitating antibodies to extractable nuclear
antigens (ENA), including Ro (SSA), La (SSB), and Sm, were
detected using a standardized enzyme-linked immunosor-
bent assay (ELISA) method and were considered positive if
higher than 1580. The levels of IgG and IgM anticardiolipin
antibodies (aCL) were measured by ELISA (21). Lupus
anticoagulant (LA) activity was detected by coagulation
assays in platelet-free plasma obtained by double centrifuga-
tion following the recommendations of the Scientific and
Standardization Committee of the International Society of
Thrombosis and Homeostasis subcommittee on LA (22).
These measurements were performed twice at an interval of
12 weeks.
Disease Activity/Cumulative Damage Evaluation
Disease activity was measured by the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) (23).
The SLEDAI consists of 24 weighted items grouped into 9
domains, or organ systems, as follows: central nervous
system (assigned a weight of 8), vascular system (weight
of 8), renal system (weight of 4), musculoskeletal system
(weight of 4), serosal system (weight of 2), dermal system
(weight of 2), immune system (weight of 2), constitu-
tional (weight of 1), and hematologic system (weight of
1). The SLEDAI scores range between 0 and 105, and
scores of $3 were considered to represent active disease
(24).
Cumulative SLE-related damage in all patients was
determined using the Systemic Lupus International
Collaborating Clinics (SLICC)/ACR Damage Index (SDI)
measured at the time of blood withdrawal. The SDI scores
ranged from 0 to 47 (25).
IFN-a assay
Peripheral venous blood was collected from each subject
and allowed to clot at room temperature for 30 min.
Samples were then centrifuged for 15 min at 3000 rpm.
Separated sera were stored in aliquots at 280˚C for
subsequent use in assays. None of the samples were taken
during an episode of acute or chronic infection (26).
Commercially available kits from R&D Systems (London,
UK) were used to measure serum IFN-a levels by ELISA in
accordance with the manufacturer’s instructions.
IFN-a and childhood-onset systemic lupus erythematosus
Postal M et al.
CLINICS 2012;67(2):157-162
158Statistical analyses
An analysis of variance with Tukey’s pairwise post hoc
comparisons was used to compare IFN-a levels between
groups. Spearman’s correlation was used to correlate
continuous variables (e.g., IFN-a levels and SLEDAI, SDI).
IFN-a levels and categorical variables were compared using
a 2-sample t-test. For all of the analyses, p-values ,0.05 were
considered statistically significant.
RESULTS
Demographics
We included 57 consecutive childhood-onset SLE
patients. Fifty-four (94.7%) were female with a mean age
of 17.33 years [standard deviation (SD) ¡4.50 years; range
9-37]. Disease duration was 4.71 years (SD¡4.57; range 0-
26). We also investigated 64 first-degree relatives with a
mean age of 39.95 years (SD¡5.66; range 28-52). The control
group consisted of 57 healthy volunteers (52 women) with a
mean age of 19.30 (SD¡4.97 years; range 6-30) (Table 1).
Patients and healthy controls were statistically compar-
able in terms of age and sex.
Clinical, laboratory, and treatment features
At the time of study entry, 30 (52.6%) childhood-onset
SLE patients had active disease (SLEDAI$3) with mean
SLEDAI scores of 8.37 (SD¡3.80, range 3-18). Patients with
inactive disease [N=27 (47.4%)] had a mean SLEDAI score
of 0.39 [(SD¡0.80 range 0-2)]. Active nephritis (28.3%), new
malar rash (6.6%), new alopecia (5.0%), and cutaneous
vasculitis (5.0%) were the most frequently observed clinical
manifestations.
At the time of blood withdrawal, 8 (13.3%) patients were
not taking any medication. Thirty-nine (68.4%) patients
were receiving prednisone, 32 (53.3%) were receiving
hydroxychloroquine, and 22 (36.6%) patients were receiving
other immunosuppressive drugs (Table 1).
Cytokine assay
The mean serum IFN-a level was 13.84¡8.46 pg/mL in
childhood-onset SLE patients, 10.36¡6.04 pg/mL (p=0.012)
in first-degree relatives and 11.68¡6.66 pg/mL in healthy
controls (p=0.043). No difference in serum IFN-a levels
between first-degree relatives and healthy controls was
observed (p=0.484) (Figure 1a).
IFN-a levels were significantly increased in patients who
were positive for dsDNA antibodies (p=0.011) (Figure 1b),
patients with cutaneous vasculitis (p=0.001), and patients
with a new malar rash (p=0.032) or disease activity
(p=0.031). IFN-a levels were directly correlated with C3
levels (r=0.34; p=0.032) and SLEDAI scores (r=0.43;
p=0.012) and indirectly correlated with age (r=-0.17;
p=0.025). IFN-a levels were significantly higher in patients
who were not taking medication (mean=13.01; SD¡6.09)
compared to patients who were receiving medication
(mean=21.59; SD¡16.02; p=0.035) (Figure 1c). In an
analysis of individual medications, higher levels of IFN-a
were observed in patients not taking prednisone
(mean=20.07; SD¡14.65) compared to patients taking
prednisone (mean=12.95; SD¡6.19; p=0.042). No associa-
tion between IFN-a levels and other clinical or laboratory
variables (hematological or immunological) or SDI scores
was observed. No difference in IFN-a levels was observed
between patients with and without hydroxychloroquine or
other immunosuppressants.
DISCUSSION
Cytokines are low-molecular weight proteins that play a
key role in the immunological dysregulation observed in
autoimmune diseases. The increased levels of proinflamma-
tory cytokines are believed to be critical in the pathogenesis
of SLE (27). Higher cytokine levels in SLE patients may
promote the inflammatory response, apoptosis and auto-
antibody production, which initiate and may also maintain
SLE disease activity over time (16,27).
The first cytokine abnormality documented in SLE was an
increased serum level of IFN-a, which is a cytokine with
both antiviral and immunoregulatory functions (17,28). The
contributions of IFN-a to SLE can be explained through
several distinct, but related, mechanisms. In genetically
susceptible individuals, B cell precursors expressing self-
reactive antibodies are not removed (15). Most likely due to
a mismanagement of naturally occurring apoptotic cells,
nuclear material stimulates autoreactive B-cells, leading to
antibody secretion and the formation of immune complexes.
Table 1 - Demographic and clinical characteristics of the patient and control groups included in the study.
Parameter
Childhood-onset SLE patients
N=57
First-degree relatives
N=64
Controls
N=57
Sex
Female 54 (94.7%) 59 (92.18%) 52 (91.22%)
Age (years) 17.33¡4.50
(range 9-37)
39.95¡5.66*
(range 28-52)
19.30¡4.97
(range 6-30)
Disease duration (years) 4.71 ¡4.57
(range 0-26)
----- -----
SLEDAI
Active disease N=30
Inactive disease N=27
4.43¡4.94
8.37¡3.80
0.39¡0.80
----- -----
SDI 0.50¡0.82 ----- -----
Treatment
No medication
Prednisone
Hydroxychloroquine
Immunosuppressive
8 (14%)
39 (68.4%)
32 (56.1%)
22 (38.6%)
IFN-a (pg/mL) 13.84¡8.46* 10.36¡6.04 11.68¡6.66
*p#0.05.
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plasmacytoid dendritic cells to produce IFN-a, which in
turn enhances antigen presentation by dendritic cells to T-
cells while promoting memory T-cell expansion and
survival (15,29).
Increased IFN-a serum levels are often observed in SLE
patients (3,17,18,30-34). Here, we observed increased serum
IFN-a in childhood-onset SLE patients compared to their
first-degree relatives or healthy controls. Our data support
the results of previous studies that demonstrated elevated
IFN-a levels in the sera of adult-onset SLE patients
(3,17,18,30-35).
The clinical significance of IFN-a pathway activation in SLE
ismultifaceted.IFN-a hasbeenimplicatedinthe pathogenesis
of SLE, and therefore, therapies targeted against IFN-a are
currently in clinical trials (36,37). Furthermore, IFN-a activa-
tion may determine specific subset of SLE patients with
potential diagnostic,prognostic, andtherapeutic implications.
Importantly, a change in IFN-a activity levels may reflect
changes in disease activity and thus inform the clinical
management of the disease (38). In our study, IFN-a was
significantly higher in patients with active disease (SLEDAI
$3) than in patients with inactive disease. Furthermore, we
observed a direct correlation between SLEDAI scores and
IFN-a levels, suggesting that IFN-a could be a biomarker for
disease activity in childhood SLE. Similar results have been
observed in adult-onset SLE (3,17,18,30-35).
Previous studies suggest that IFN-a plays an important
role in the immunopathogenesis of SLE (3,17,18,30-35).
Serum IFN-a is correlated with multiple clinical and
serological features of SLE (29,35). We observed that IFN-a
levels were increased in patients with cutaneous manifesta-
tions of the disease. Our data also showed increased IFN-a
levels in childhood-onset SLE patients positive for dsDNA
antibodies as well as a direct correlation between IFN-a and
C3 levels. However, no association with renal disease was
observed. The increased expression of IFN-inducible genes
(IFIGs) in peripheral blood mononuclear cells (PBMCs) has
been associated with the presence of lupus nephritis and
proteinuria, cutaneous manifestations, and the presence of
anti-Ro, anti-Smith (anti-Sm), anti-RNP, and anti-dsDNA
antibodies (32,39). Anti-dsDNA antibodies have been
associated with lupus nephritis (40), and studies have
linked anti-Ro antibody to lupus-related skin findings (41).
It remains unclear whether the association between IFN-a
and cutaneous and renal disease manifestations found in
previous studies is primary or secondary due to an
association between autoantibodies and IFN-a (39). We
did not observe any associations between IFN-a levels and
the levels of other antibodies, such as anti-Ro, anti-Sm, or
anti-RNP.
Relatives of individuals with SLE are at a higher risk
of developing not only SLE but also other autoimmune
diseases (3,31). A heritable predisposition to increased IFN-
a pathway activation in SLE patient families could explain
some of the burden of both SLE and non-SLE autoimmu-
nity in the population. Single nucleotide polymorphisms
(SNPs) in the IFN-a pathway genes IFN regulatory factor 5
(IRF5) and non-receptor tyrosine-protein kinase (TYK2)
(42-45) are associated with SLE, suggesting that genetic
variability in endogenous IFN-a signaling may be involved
in the etiology of this disease, although the impact of these
polymorphisms on IFN-a activity in vivo is not known
(3,43). We did not observe any differences in serum IFN-a
levels between first-degree relatives of SLE patients and
controls. However, the limited sample size may have
affected these results.
We found an inverse correlation between patient age and
IFN-a levels. Similar findings have been reported in adult
SLE patients as well as in healthy controls, independent of
menopause status (31). It is not clear whether the higher
serum IFN-a activity observed in young SLE patients is a
cause or a result of disease activity, but this correlation may
explain some of the differences in the clinical and serologic
manifestations of childhood-onset and adult-onset SLE
patients.
In addition, we observed higher IFN-a levels in patients
who were not receiving medication. None of these patients
had any evidence of disease activity at the time of
evaluation. Previous studies have shown a dramatic
decrease in the expression of IFN-inducible genes (IFIGs)
in patients who received pulse glucocorticoid (GC) therapy
Figure 1 - IFN-a association in SLE. 1a- Analysis of variance with Tukey’s pairwise post-hoc comparisons among SLE patients, their first-
degree relatives and controls; 1b- 2-sample t-test comparing SLE patients positive and negative for dsDNA antibodies; 1c- 2-sample t-
test comparing SLE patients taking and not taking medication. Data are presented as box plots; the box represents the 25th to 75th
percentiles, the line within the box represents the 50th percentile, and the lines outside the box represent the minimum and maximum
values.
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pulse GC treatment may decrease the number of IFN-
producing cells, transiently reducing the stimulus for IFIG
expression (47).
Although previous studies have analyzed IFN-a levels
in childhood-onset SLE, none of these studies have
analyzed the clinical and laboratory features associated
with increased IFN-a levels (31,45). Serum IFN-a activity
was found to be higher in younger individuals in SLE
family cohorts, and this tendency was accentuated in
affected individuals (31). In addition, one other study
revealed that childhood-onset SLE patients are character-
ized by a potent IFN-a response (45). Genomic approaches
have shown that .95% of childhood-onset SLE patients
display an ‘‘IFN signature’’, as measured by PBMC gene
expression profiling (45,48). The PBMC transcriptional
signature in childhood-onset SLE corresponds to neutro-
phil-specific genes, and the differential expression of these
genes correlates with disease activity (45). Notably, SLE
neutrophils undergo accelerated spontaneous apoptosis in
vitro, and SLE sera induce apoptosis in healthy neutrophils,
both of which are correlated with disease activity (49). In
addition, the IFIG expression signature can be used to
establish subgroups of patients with severe SLE character-
ized by renal disease, complement activation, and autoanti-
body production to RNA-associated autoantigens (33,50).
Genetic association studies of SLE patients have identified
several genes, especially components of the pathways both
upstream and downstream of IFN (mainly type I), including
signal transducer and activator of transcription 4 (STAT4)
and IRF5 (38,51-53). STAT4 interacts with type I IFN
receptors and is directly involved in IFN signaling. IRF5 is
a transcription factor that induces IFN transcription in
response to Toll-like receptor (TLR) signaling. In fact, the
IRF5 risk haplotype in SLE patients is associated with high
serum IFN-a activity (34). These findings are consistent with
the fundamental observations from a previous study that
identified gene expression profiling of SLE PBMCs (38).
These experiments demonstrate a significant upregulation
of IFN-regulated gene transcripts in adult and childhood-
onset SLE PBMCs (32,34). This characteristic is referred to as
the ‘‘IFN signature’’ and is assessed as a biomarker for
disease activity (38).
In summary, our findings suggest that IFN-a may play a
role in the pathogenesis of childhood-onset SLE. The higher
levels observed in younger children may explain the
different clinical and serologic manifestations when com-
pared to older patients. The pattern of increased IFN-a
levels in patients not taking medication should be investi-
gated further in longitudinal studies to determine whether
elevated IFN-a levels may predict SLE flares.
ACKNOWLEDGMENTS
Fundac ¸a ˜o de Amparo A ` Pesquisa Estado Sa ˜o Paulo-Brasil (FAPESP 2008/
02917-0, 2009/06049-6, 2009/11076-2, 2010/13636-2, 2010/13637-9),
Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/
2009-4)
AUTHOR CONTRIBUTIONS
Postal M designed the study and was also responsible for data collection,
data analysis and manuscript writing. Sinicato NA was responsible for the
collection and analysis of data. Pelic ¸ari KO was responsible for the data
collection. Marini R designed the study and was also responsible for the
data collection and manuscript writing. Costallat LTL was responsible for
the manuscript writing. Appenzeller S designed the study and was also
responsible for the collection and analysis of data and manuscript writing.
REFERENCES
1. Lee HM, Mima T, Sugino H, Aoki C, Adachi Y, Yoshio-Hoshino N, et al.
Interactions among type I and type II interferon, tumor necrosis factor,
and beta-estradiol in the regulation of immune response-related gene
expressions in systemic lupus erythematosus. Arthritis Res Ther.
2009;11:R1, http://dx.doi.org/10.1186/ar2584.
2. Kotzin B. Systemic lupus erythematosus. Cell. 1996;85:303-306.
3. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-
alpha activity is a heritable risk factor for systemic lupus erythematosus.
Genes Immun. 2007;8:492-502, http://dx.doi.org/10.1038/sj.gene.636
4408.
4. Brunner HI, Gladman DD, Iban ˜ez D, Urowitz MD, Silverman ED.
Difference in disease features between childhood-onset and adult-onset
systemic lupus erythematosus. Arthritis Rheum. 2008;58:556-62, http://
dx.doi.org/10.1002/art.23204.
5. Mina R, Brunner HI. Pediatric lupus–are there differences in presenta-
tion, genetics, response to therapy, and damage accrual compared with
adult lupus? Rheum Dis Clin North Am. 2010;36:53-80, http://
dx.doi.org/10.1016/j.rdc.2009.12.012.
6. Font J, Cervera R, Espinosa G, Pallare ´s L, Ramos-Casals M, Jime ´nez S,
et al. Systemic lupus erythematosus (SLE) in childhood: analysis of
clinical and immunological findings in 34 patients and comparison with
SLE characteristics in adults. Ann Rheum Dis. 1998;57:456–9, http://
dx.doi.org/10.1136/ard.57.8.456.
7. Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D,
Cebecauer L, et al. Juvenile-onset systemic lupus erythematosus:
different clinical and serological pattern than adult-onset systemic lupus
erythematosus. Ann Rheum Dis 2009;68:412–5.
8. Carreno L, Lopez-Longo FJ, Monteagudo I, Rodrı ´guez-Mahou M,
Bascones M, Gonza ´lez CM, et al. Immunological and clinical differences
between juvenile and adult onset of systemic lupus erythematosus.
Lupus. 1999;8:287–92, http://dx.doi.org/10.1191/096120399678847786.
9. Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L,
et al. Differences in long-term disease activity and treatment of adult
patients with childhood- and adult-onset systemic lupus erythematosus.
Arthritis Rheum. 2009;61:13–20.
10. Sibbitt WL Jr, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC,
et al. The incidence and prevalence of neuropsychiatric syndromes
in pediatric onset systemic lupus erythematosus. J Rheumatol.
2002;29:1536–42.
11. Rood MJ, ten Cate R, van Suijlekom-Smit LW, den Ouden EJ, Ouwerkerk
FE, Breedveld FC, et al. Childhood-onset Systemic Lupus
Erythematosus: clinical presentation and prognosis in 31 patients.
Scand J Rheumatol. 1999;28:222–6.
12. von Scheven E, Bakkaloglu A. What’s new in paediatric SLE? Best Pract
Res Clin Rheumatol. 2009;23:699-708, http://dx.doi.org/10.1016/
j.berh.2009.07.008.
13. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-
onset systemic lupus erythematosus: a comparison of onset, clinical
features, serology, and outcome. Br J Rheumatol. 1995;34:866-72.
14. Appenzeller S, Marini R, Costallat LT. Damage did not independently
influence mortality in childhood systemic lupus erythematosus.
Rheumatol Int. 2005;25:619-24, http://dx.doi.org/10.1007/s00296-004-
0552-z.
15. Ro ¨nnblom L, Alm GV. Systemic lupus erythematosus and the type I
interferon system. Arthritis Res Ther. 2003;5:68-75, http://dx.doi.org/
10.1186/ar625.
16. Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in
systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:948364.
17. Hooks JJ, Moutsopoulos HM, Geis AS, Stahl NI, Decker JL, Notkins AL.
Immune interferon in the circulation of patients with autoimmune
disease. N Engl J Med. 1979;301:5-8.
18. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with
systemic lupus erythematosus. Arthritis Rheum. 1982;25:401-6.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al.
The 1982 revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum. 1982;25:1271–7, http://dx.doi.org/
10.1002/art.1780251101.
20. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomencalture. The
American College of Rheumatology nomenclature and case definitions
for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–
608, http://dx.doi.org/10.1002/1529-0131(199904)42:4,599::AID-
ANR2.3.0.CO;2-F.
21. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-
cardiolipin antibody test: report of an international workshop held 4
April 1986. Clin Exp Immunol. 1987;68:215–22.
22. Brandt JT, Triplett DA, Alving B, Scharrer I, , on behalf of the
Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of
the Scientific and Standardisation Committee of the ISTH. Criteria for the
CLINICS 2012;67(2):157-162 IFN-a and childhood-onset systemic lupus erythematosus
Postal M et al.
161diagnosis of lupus anticoagulants: an update. Thromb Haemost.
1995;74:1185–90.
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH.
Derivation of the SLEDAI. A disease activity index for lupus patients.
The Committee on Prognosis Studies in SLE. Arthritis Rheum.
1992;35:630–40.
24. Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al.
The use of Systemic Lupus Erythematosus Disease Activity Index-2000
to define active disease and minimal clinically meaningful change based
on data from a large cohort of systemic lupus erythematosus patients.
Rheumatology (Oxford). 2011;50:982-8, http://dx.doi.org/10.1093/
rheumatology/keq376.
25. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon
C, et al. The reliability of the Systemic Lupus International Collaborating
Clinics/American College of Rheumatology Damage Index in patients
with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809–13,
http://dx.doi.org/10.1002/art.1780400506.
26. Galley HF, Webster NR. The immuno-inflammatory cascade.Br J
Anaesth. 1996;77:11-6.
27. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A.
Chloroquine treatment influences proinflammatory cytokine levels in
systemic lupus erythematosus patients. Lupus. 2006;15:268-75, http://
dx.doi.org/10.1191/0961203306lu2299oa.
28. Golding A, Rosen A, Petri M, Akhter E, Andrade F. Interferon-alpha
regulates the dynamic balance between human activated regulatory and
effector T cells: implications for antiviral and autoimmune responses.
Immunology. 2010;131:107-17.
29. Zhang R, Xing M, Ji X, Gu L, Yang X, Wang H, et al. Interferon-alpha and
interleukin-6 in SLE serum induce the differentiation and maturation of
dendritic cells derived from CD34+ hematopoietic precursor cells.
Cytokine. 2010;50:195-203, http://dx.doi.org/10.1016/j.cyto.2010.02.017.
30. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum
levels of interferons in patients with systemic lupus erythematosus. Clin
Exp Immunol. 1987;70:562-9.
31. Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Age-
and sex-related patterns of serum interferon-alpha activity in lupus
families. Arthritis Rheum. 2008;58:2113-9, http://dx.doi.org/10.1002/
art.23619.
32. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe
KJ, et al. Interferon-inducible gene expression signature in peripheral
blood cells of patients with severe lupus. Proc Natl Acad Sci U S A.
2003;100:2610–5, http://dx.doi.org/10.1073/pnas.0337679100.
33. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation
of the interferon-alpha pathway identifies a subgroup of systemic lupus
erythematosus patients with distinct serologic features and active
disease. Arthritis Rheum. 2005;52:1491–503, http://dx.doi.org/10.1002/
art.21031.
34. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK.
Association of the IRF5 risk haplotype with high serum interferon-alpha
activity in systemic lupus erythematosus patients. Arthritis Rheum.
2008;58:2481–7, http://dx.doi.org/10.1002/art.23613.
35. Dall’era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I
interferon correlates with serological and clinical manifestations of SLE.
Ann Rheum Dis. 2005;64:1692-7, http://dx.doi.org/10.1136/ard.2004.
033753.
36. Ro ¨nnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev
Rheumatol. 2010;6339-47.
37. Yoo DH. Anticytokine therapy in systemic lupus erythematosus. Lupus.
2010;19:1460-7, http://dx.doi.org/10.1177/0961203310376955.
38. Obermoser G, Pascual V. The interferon-alpha signature of systemic
lupus erythematosus. Lupus. 2010;19:1012-9, http://dx.doi.org/10.1177/
0961203310371161.
39. Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL,
et al. Network analysis of associations between serum interferon alpha
activity, autoantibodies, and clinical features in systemic lupus erythe-
matosus. Arthritis Rheum. 2011;63:1044-53, http://dx.doi.org/10.1002/
art.30187.
40. Bastian HM, Alarcon GS, Roseman JM, McGwin G Jr, Vila ´ LM, Fessler BJ,
et al. Systemic lupus erythematosus in a multiethnic US cohort
(LUMINA) XL II: factors predictive of new or worsening proteinuria.
Rheumatology (Oxford) 2007;46:683-9.
41. Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P, Gilliam
JN. Serologic and HLA associations in subacute cutaneous lupus
erythematosus, a clinical subset of lupus erythematosus. Ann Intern
Med 1982;97:664-71.
42. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW,
et al. A common haplotype of interferon regulatory factor 5 (IRF5)
regulates splicing and expression and is associated with increased risk of
systemic lupus erythematosus. Nat Genet. 2006;38:550–5, http://
dx.doi.org/10.1038/ng1782.
43. Rullo OJ, Woo JM, Wu H, Hoftman AD, Maranian P, Brahn BA, et al.
Association of IRF5 polymorphisms with activation of the interferon
alpha pathway. Ann Rheum Dis. 2010;69:611-7, http://dx.doi.org/
10.1136/ard.2009.118315.
44. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al.
Interferon-regulated chemokines as biomarkers of systemic lupus
erythematosus disease activity: a validation study. Arthritis Rheum.
2009;60:3098-107, http://dx.doi.org/10.1002/art.24803.
45. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al.
Netting neutrophils are major inducers of type I IFN production in
pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3:73ra20,
http://dx.doi.org/10.1126/scitranslmed.3001201.
46. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation
of the interferon-alpha pathway identifies a subgroup of systemic lupus
erythematosus patients with distinct serologic features and active
disease. Arthritis Rheum. 2005;52:1491-503, http://dx.doi.org/10.1002/
art.21031.
47. Shodell M, Shah K, Siegal FP. Circulating human plasmacytoid dendritic
cells are highly sensitive to corticosteroid administration. Lupus 2003;
12:222–30.
48. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al.
Interferon and granulopoiesis signatures in systemic lupus erythemato-
sus blood. J. Exp. Med. 2003;197:711–23, http://dx.doi.org/10.1084/
jem.20021553.
49. Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW. The role
of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus.
Arthritis Rheum. 2009;60:2390–401, http://dx.doi.org/10.1002/art.
24634.
50. Flesher DL, Sun X, Behrens TW, Graham RR, Criswell LA. Recent
advances in the genetics of systemic lupus erythematosus. Expert Rev
Clin Immunol. 2010;6:461-79, http://dx.doi.org/10.1586/eci.10.8.
51. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, et al. A
large-scale replication study id e n t i f i e sT N I P 1 ,P R D M 1 ,J A Z F 1 ,
UHRF1BP1 and IL10 as risk loci forsystemic lupus erythematosus. Nat
Genet. 2009;41:1228-33, http://dx.doi.org/10.1038/ng.468.
52. Sigurdsson S, Nordmark G, Go ¨ring HH, Lindroos K, Wiman AC, Sturfelt
G, et al. Polymorphisms in the tyrosine kinase 2 and interferon
regulatory factor 5 genes are associatedwith systemic lupus erythema-
tosus. Am J Hum Genet. 2005;76:528-37.
53. International Consortium for Systemic Lupus Erythematosus Genetics
(SLEGEN), Harley JB, Alarco ´n-Riquelme ME, Criswell LA, Jacob CO,
Kimberly RP, et al. Genome-wide association scan in women with
systemic lupus erythematosus identifiessusceptibility variants in
ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40:204-10,
http://dx.doi.org/10.1038/ng.81.
IFN-a and childhood-onset systemic lupus erythematosus
Postal M et al.
CLINICS 2012;67(2):157-162
162